308 related articles for article (PubMed ID: 22913735)
1. Linagliptin: a review of its use in the management of type 2 diabetes mellitus.
Deeks ED
Drugs; 2012 Sep; 72(13):1793-824. PubMed ID: 22913735
[TBL] [Abstract][Full Text] [Related]
2. Linagliptin: in type 2 diabetes mellitus.
Scott LJ
Drugs; 2011 Mar; 71(5):611-24. PubMed ID: 21443284
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.
Owens DR; Swallow R; Dugi KA; Woerle HJ
Diabet Med; 2011 Nov; 28(11):1352-61. PubMed ID: 21781152
[TBL] [Abstract][Full Text] [Related]
4. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial.
Gallwitz B; Rosenstock J; Rauch T; Bhattacharya S; Patel S; von Eynatten M; Dugi KA; Woerle HJ
Lancet; 2012 Aug; 380(9840):475-83. PubMed ID: 22748821
[TBL] [Abstract][Full Text] [Related]
5. Linagliptin: an update of its use in patients with type 2 diabetes mellitus.
McKeage K
Drugs; 2014 Oct; 74(16):1927-1946. PubMed ID: 25297911
[TBL] [Abstract][Full Text] [Related]
6. Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes.
Forst T; Uhlig-Laske B; Ring A; Graefe-Mody U; Friedrich C; Herbach K; Woerle HJ; Dugi KA
Diabet Med; 2010 Dec; 27(12):1409-19. PubMed ID: 21059094
[TBL] [Abstract][Full Text] [Related]
7. Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy.
Barnett AH
Adv Ther; 2011 Jun; 28(6):447-59. PubMed ID: 21603986
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial.
Ross SA; Rafeiro E; Meinicke T; Toorawa R; Weber-Born S; Woerle HJ
Curr Med Res Opin; 2012 Sep; 28(9):1465-74. PubMed ID: 22816729
[TBL] [Abstract][Full Text] [Related]
9. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
Barnett AH; Patel S; Harper R; Toorawa R; Thiemann S; von Eynatten M; Woerle HJ
Diabetes Obes Metab; 2012 Dec; 14(12):1145-54. PubMed ID: 22974280
[TBL] [Abstract][Full Text] [Related]
10. Vildagliptin: a review of its use in type 2 diabetes mellitus.
Keating GM
Drugs; 2010 Nov; 70(16):2089-112. PubMed ID: 20964454
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial.
Lewin AJ; Arvay L; Liu D; Patel S; von Eynatten M; Woerle HJ
Clin Ther; 2012 Sep; 34(9):1909-19.e15. PubMed ID: 22939034
[TBL] [Abstract][Full Text] [Related]
12. [Jentadueto, fixed combination of linagliptin plus metformin for the treatment of type 2 diabetes].
Scheen AJ; Van Gaal LF
Rev Med Liege; 2013 Sep; 68(9):479-85. PubMed ID: 24180204
[TBL] [Abstract][Full Text] [Related]
13. Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study.
Kawamori R; Inagaki N; Araki E; Watada H; Hayashi N; Horie Y; Sarashina A; Gong Y; von Eynatten M; Woerle HJ; Dugi KA
Diabetes Obes Metab; 2012 Apr; 14(4):348-57. PubMed ID: 22145698
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: pooled analysis of data from three placebo-controlled phase III trials.
Del Prato S; Taskinen MR; Owens DR; von Eynatten M; Emser A; Gong Y; Chiavetta S; Patel S; Woerle HJ
J Diabetes Complications; 2013; 27(3):274-9. PubMed ID: 23403068
[TBL] [Abstract][Full Text] [Related]
15. Initial combination of linagliptin and metformin compared with linagliptin monotherapy in patients with newly diagnosed type 2 diabetes and marked hyperglycaemia: a randomized, double-blind, active-controlled, parallel group, multinational clinical trial.
Ross SA; Caballero AE; Del Prato S; Gallwitz B; Lewis-D'Agostino D; Bailes Z; Thiemann S; Patel S; Woerle HJ; von Eynatten M
Diabetes Obes Metab; 2015 Feb; 17(2):136-44. PubMed ID: 25298165
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients.
Horie Y; Kanada S; Watada H; Sarashina A; Taniguchi A; Hayashi N; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2011 Jul; 33(7):973-89. PubMed ID: 21723606
[TBL] [Abstract][Full Text] [Related]
17. The effect of linagliptin on glycaemic control and tolerability in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
Singh-Franco D; McLaughlin-Middlekauff J; Elrod S; Harrington C
Diabetes Obes Metab; 2012 Aug; 14(8):694-708. PubMed ID: 22340363
[TBL] [Abstract][Full Text] [Related]
18. DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.
Scheen AJ
Diabetes Metab; 2012 Apr; 38(2):89-101. PubMed ID: 22197148
[TBL] [Abstract][Full Text] [Related]
19. Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study.
Haak T; Meinicke T; Jones R; Weber S; von Eynatten M; Woerle HJ
Diabetes Obes Metab; 2012 Jun; 14(6):565-74. PubMed ID: 22356132
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.
Heise T; Graefe-Mody EU; Hüttner S; Ring A; Trommeshauser D; Dugi KA
Diabetes Obes Metab; 2009 Aug; 11(8):786-94. PubMed ID: 19476474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
